Logo of Zelira Therapeutics (ASX:ZLD)Latest Zelira Therapeutics (ASX:ZLD) News

Page 2
Page 2 of 2

Zelira’s ZLT-L-007 Surpasses Lyrica® in Diabetic Neuropathy Pain Relief

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.
Ada Torres
22 May 2025

Zelira Strengthens Capital and Advances FDA Trials with New Funding Moves

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.
Ada Torres
29 Apr 2025

Zelira Therapeutics Secures $1.15M R&D Refund to Fuel Clinical Pipeline

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.
Victor Sage
18 Feb 2025

Zelira Secures US$681K Funding Boost for HOPE® Autism FDA Trials

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.
Ada Torres
30 Jan 2025

Zelira Secures $3.25M to Advance FDA Trials for HOPE® 1 in Autism-Linked Syndrome

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.
Victor Sage
28 Jan 2025